Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.19
Views: 144

Dr Catherine Smith - University of California San Francisco, San Francisco, USA

Dr Catherine Smith speaks to ecancer at the ASH 2019 meeting in Orlando about a study evaluating emerging mutations in acute myeloid leukaemia (AML) patients who relapsed while receiving gilteritinib therapy in the phase III ADMIRAL trial.

She explains that they looked at 40 patients who had relapsed on gilteritinib therapy and who were then analysed by next-generation sequencing using the Archer Core Myeloid Panel.

Dr Smith reports that in patients who relapsed the most common mutations were Ras/MAPK pathway gene mutations.

ecancer's filming has been kindly supported by AbbVie through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation